Search
Obeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigationalThe NDA from Intercept Pharmaceuticals was approved in November 2019 and obeticholic acid is expected to be granted full approval for this indication in 2020.[L12636] … [A18696,L12633] In May 2021, the FDA updated its prescribing information to contraindicate the use of obeticholic acid in patients with PBC and advanced cirrhosis (e.g. those with portal hypertension or
Diethyltoluamide
go.drugbank.com/drugs/DB11282ApprovedAnd, despite concerns over excessive exposure to the chemical, appropriate usage of the chemical at the recommended dosages and routes of administration have generally proven to be safe - even when most … DEET products are largely designed to be applied directly to human skin, where the exact mechanisms of actions in which DEET is capable of repelling insects and causing toxicity to humans is still not
Ethambutol
go.drugbank.com/drugs/DB00330ApprovedInvestigationalEthambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis. … [L31743] Ethambutol was first described in the literature in 1961.[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.
Mixtures: PRO TB 4Products: E-BUTOL TABLET 400 mgDalbavancin
go.drugbank.com/drugs/DB06219ApprovedInvestigationalDalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin [A4072, A4073]. … Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking [FDA Label, F2356, A4072
Ganaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigational[L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636] … [L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment
Mavacamten
go.drugbank.com/drugs/DB14921ApprovedInvestigationalIt received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. … [A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.[L44106,L47471]
Products: CAMZYOS® 2.5MG CAPSULAS DURAS DE LIBERACIÓN INMEDIATA.Oxybutynin
go.drugbank.com/drugs/DB01062ApprovedInvestigationalOveractive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. … Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.
Products: LYRINELTABLETAS DE 10 MG, LYRINEL TABLETAS DE 15 MGMenadione
go.drugbank.com/drugs/DB00170ApprovedNutraceuticalA synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.
Pantoprazole
go.drugbank.com/drugs/DB00213ApprovedInvestigationalAs the binding of pantoprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, pantoprazole's duration of antisecretory effect persists … This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus.
Products: Pantoprazole T, Mylan-pantoprazole TNefazodone
go.drugbank.com/drugs/DB01149ApprovedWithdrawnDrug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to … On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome